NEW YORK, June 11 - British structural proteomics company Astex Technology has joined the Global Phasing consortium, giving Astex early access to Global Phasing's software for modeling protein structure using x-ray crystallography, the companies said Monday.

Astex, based in Cambridge, UK, joins several undisclosed pharmaceutical companies in the consortium. In addition to early access to software, membership in the consortium allows Astex scientists to consult with Global Phasing software developers. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.